In second-line settings, the recent PROLUNG study found that the combination of pembrolizumab and docetaxel was well-tolerated and substantially improved the outcomes of patients with advanced NSCLC, including epidermal growth factor receptor (EGFR)-mutant NSCLC (12). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.